Abstract
Airway inflammation is central to the pathogenesis of allergic asthma, and molecules that mediate this process obviously represent targets for therapy. In the present article, we discuss our experiments, which point to CD4+ T cells and IL-5-driven eosinophilia as potential targets for the relief of bronchial hyperractivity in late-phase asthma.
Original language | English |
---|---|
Pages (from-to) | 454-460 |
Number of pages | 7 |
Journal | Immunology and Cell Biology |
Volume | 76 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1998 |